1287261-33-9

Basic information

• Product Name: (S)-methyl 2-((3-((4-methoxyphenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy) acetate
• Synonyms: (S)-methyl 2-((3-((4-methoxyphenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy) acetate
• CAS NO: 1287261-33-9
• Molecular Weight: 370.405
• Mol File: 1287261-33-9.mol

Chemical Properties

• CAS DataBase Reference: (S)-methyl 2-((3-((4-methoxyphenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy) acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-methyl 2-((3-((4-methoxyphenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy) acetate(1287261-33-9)
• EPA Substance Registry System: (S)-methyl 2-((3-((4-methoxyphenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy) acetate(1287261-33-9)

Safety Data

• Hazardous Substances Data: 1287261-33-9(Hazardous Substances Data)

Upstream product

• 142335-41-9 (S)-2-(tert-butoxycarbonyl)-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 142335-42-0 (3S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 1223620-39-0 (S)-tert-butyl 7-hydroxy-3-((4-methoxyphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-63-0 (S)-tert-butyl 7-(2-methoxy-2-oxoethoxy)-3-((4-methoxyphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Downstream Products

• 1287261-44-2 (S)-methyl 2-(3-(4-methoxyphenylcarbamoyl)-2-(2-phenylacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yloxy)acetate 
• 1287261-36-2 (S)-methyl 2-(2-(2-(tert-butoxycarbonylamino)acetyl)-3-(4-methoxyphenylcarbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yloxy)acetate 
• 1287261-51-1 (S)-tert-butyl 2-((2S,3S)-1-((S)-7-(2-methoxy-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-1-oxopentan-2-ylcarbamoyl)pyrrolidine-1-carboxylate 
• 1287261-53-3 tert-butyl 4-((2S,3S)-1-((S)-7-(2-methoxy-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-1-oxopentan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 1287261-61-3 methyl 2-((S)-2-((2S,3S)-2-(3,3-dimethylbutanamido)-3-methylpentyl)-3-(4-methoxyphenylcarbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yloxy)acetate 
• 1287261-29-3 (S)-2-((2S,3S)-2-(3,3-dimethylbutanamido)-3-methylpentyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1287261-11-3 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-2-(3-phenylpropyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1287261-13-5 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1287261-12-4 (S)-2-benzyl-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1287261-22-6 (S)-tert-butyl 2-((2S,3S)-1-((S)-7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-1-oxopentan-2-ylcarbamoyl)pyrrolidine-1-carboxylate 
• 1287261-23-7 tert-butyl (S)-1-((2S,3S)-1-((S)-7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1287261-24-8 tert-butyl 4-((2S,3S)-1-((S)-7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-1-oxopentan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 1287261-25-9 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-2-((2S,3S)-3-methyl-2-((S)-pyrrolidine-2-carboxamido)-pentanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride 
• 1287261-26-0 (S)-2-((2S,3S)-2-((S)-2-amino-3-methylbutanamido)-3-methylpentanoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride 

Relevant articles and documents

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: Potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities

Inhibition of histone deacetylase (HDAC) results in growth arrest, differentiation, and apoptosis in nearly all tumor cell lines, promoting HDACs as promising targets for antitumor therapy. In our previous study we developed a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as HDAC inhibitors (HDACi), among which compound 7d exhibited promising HDAC8 inhibitory and antiproliferative activities. Herein, we report the design and development of a new class of tetrahydroisoquinoline-bearing hydroxamic acid analogues as potential HDACi and anticancer agents. In vitro biological evaluation of these compounds showed improved HDAC8 inhibition (compounds 31a and 31b exhibited mid-nM IC50 values against HDAC8) and potent growth inhibition in multiple tumor cell lines. Most importantly, compounds 25e, 34a, and 34b exhibited excellent in vivo anticancer activities in a human breast carcinoma (MDA-MB-231) xenograft model compared with suberoylanilide hydroxamic acid (SAHA), an approved HDACi. Collectively, our results indicate that tetrahydroisoquinoline bearing a hydroxamic acid is an excellent template to develop novel HDACi as potential anticancer agents.

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities

Histone deacetylase (HDAC) has emerged as an attractive target for the development of antitumor agents during the past decade. Previously tetrahydroisoquinoline-bearing hydroxamic acid analogue, ZYJ-25e (1), was identified and validated as a potent histone deacetylase inhibitor (HDACi) with marked in vitro and in vivo antitumor potency. In the present study, further modification of 1 led to another more potent, orally active HDACi, ZYJ-34c (4). Compared to FDA-approved drug suberoylanilide hydroxamic acid (SAHA), compound 4 exhibited higher in vivo antitumor potency in a human breast carcinoma (MDA-MB-231) xenograft model and in a mouse hepatoma-22 (H22) pulmonary metastasis model and similar in vivo antitumor potency in a human colon tumor (HCT116) xenograft model.